Document Detail


Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin.
MedLine Citation:
PMID:  17260141     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: Foregut carcinoid tumours have a different embryological origin than other gastroenteropancreatic neuroendocrine tumours (GEP NETs). In the total group of GEP NETs (n = 131), treatment with (177)Lu-octreotate resulted in tumour remission in 47% of patients, with a median time to progression (TTP) of >36 months. As patients with foregut carcinoids may respond differently, we here present the effects of this treatment in a subgroup of patients with foregut carcinoids of bronchial, gastric or thymic origin.
METHODS: Nine patients with bronchial, five with gastric and two with thymic carcinoids were treated. All patients had metastasised disease. The intended cumulative dose of (177)Lu-octreotate was 22.2-29.6 GBq. Southwest Oncology Group criteria were used for response evaluation.
RESULTS: Bronchial carcinoids: Five patients had partial remission, one had minor response (MR, tumour size reduction: > or =25%, <50%), two had stable disease (SD) and one had progressive disease (PD). Median TTP was 31 months. Gastric carcinoids: One patient had complete remission, one had MR and two had SD, including one with PD at baseline. One patient developed PD. Thymic carcinoids: One patient had SD. In the other patient, disease remained progressive. All patients: Overall remission rate was 50%, including MR.
CONCLUSION: (177)Lu-octreotate treatment can be effective in patients with bronchial and gastric carcinoids. Its role in thymic carcinoids cannot be determined yet because of the limited number of patients. The overall remission rate of 50% in patients with the studied foregut carcinoids is comparable to that in the total group of GEP NETs.
Authors:
Martijn van Essen; Eric P Krenning; Willem H Bakker; Wouter W de Herder; Maarten O van Aken; Dik J Kwekkeboom
Publication Detail:
Type:  Journal Article     Date:  2007-01-27
Journal Detail:
Title:  European journal of nuclear medicine and molecular imaging     Volume:  34     ISSN:  1619-7070     ISO Abbreviation:  Eur. J. Nucl. Med. Mol. Imaging     Publication Date:  2007 Aug 
Date Detail:
Created Date:  2007-08-21     Completed Date:  2007-12-20     Revised Date:  2011-01-03    
Medline Journal Info:
Nlm Unique ID:  101140988     Medline TA:  Eur J Nucl Med Mol Imaging     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  1219-27     Citation Subset:  IM    
Affiliation:
Department of Nuclear Medicine, Erasmus MC, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. m.vanessen@erasmusmc.nl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Bronchial Neoplasms / radiotherapy*
Carcinoid Tumor / radiotherapy*
Disease Progression
Female
Humans
Lutetium / therapeutic use*
Male
Medical Oncology / methods
Middle Aged
Octreotide / analogs & derivatives*,  chemistry
Peptides / chemistry*
Radioisotopes / therapeutic use*
Remission Induction
Stomach Neoplasms / radiotherapy*
Thymus Neoplasms / radiotherapy*
Treatment Outcome
Chemical
Reg. No./Substance:
0/177Lu-octreotate; 0/Peptides; 0/Radioisotopes; 7439-94-3/Lutetium; 83150-76-9/Octreotide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Reduction and partial degradation mechanisms of naphthylaminesulfonic azo dye amaranth by Shewanella...
Next Document:  Risk factors for clinical anastomotic leakage and postoperative mortality in elective surgery for re...